+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Schizophrenia with ethyl-eicosapentaenoate A randomized, placebo-controlled trial

Treatment of Schizophrenia with ethyl-eicosapentaenoate A randomized, placebo-controlled trial

Journal of Molecular Neuroscience 16(2-3): 328, April-June

(PDF 0-2 workdays service: $29.90)

Accession: 035980610

Download citation: RISBibTeXText

Related references

Ethyl-eicosapentaenoate in Huntingtons Disease A randomised, placebo-controlled Trial. Neurology 60(5 Supplement 1): A246-A247, March 11, 2003

A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. Journal of Clinical Psychiatry 70(12): 1636-1644, 2010

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. American Journal of Psychiatry 159(9): 1596-1598, 2002

Treatment of Huntingtons disease with ethyl-eicosapentaenoic acid A randomized, placebo-controlled trial. Journal of Molecular Neuroscience 16(2-3): 328-329, April-June, 2001

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry 54(11): 1241-1248, 2003

Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Global Journal of Health Science 6(7 Spec No): 103-108, 2015

Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. International Clinical Psychopharmacology 26(6): 303-310, 2012

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 162(1): 130-136, 2004

Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. Psychiatry Research 219(3): 431-435, 2015

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. Journal of Clinical Psychiatry 72(3): 349-355, 2011

Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Schizophrenia Bulletin 36(4): 846-851, 2010

Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Patents on Inflammation & Allergy Drug Discovery 8(3): 211-215, 2015

Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Journal of Clinical Psychiatry 66(8): 1012-1015, 2005

The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophrenia Research 116(2-3): 101-106, 2010

Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. Journal of Clinical Psychopharmacology 33(2): 243-247, 2013